Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids
Titel:
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids
Auteur:
Frost, Nikolaj Kollmeier, Jens Misch, Daniel Vollbrecht, Claudia Grah, Christian Matthes, Burkhard Pultermann, Dennis Olive, Elisabeth Raspe, Matthias Ochsenreither, Sebastian von Laffert, Maximilian Suttorp, Norbert Witzenrath, Martin Grohé, Christian